We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bovie Medical Corp. | AMEX:BVX | AMEX | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.48 | 0.00 | 01:00:00 |
|
|
|
|
|
|
ý
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended September 30, 2017
|
|
or
|
|
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from _____ to _____
|
Commission File Number: 0-12183
|
|
BOVIE MEDICAL CORPORATION
|
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
11-2644611
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
|
|
|
|
|
Page
|
Part I.
|
|
|
||
|
|
|
|
|
Item 1.
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
|
|
Item 2.
|
|
|
||
Item 3.
|
|
|
||
Item 4.
|
|
|
||
|
|
|
|
|
Part II.
|
|
|
||
|
|
|
|
|
Item 1.
|
|
|
||
Item 1A.
|
|
|
||
Item 2.
|
|
|
||
Item 3.
|
|
|
||
Item 4.
|
|
|
||
Item 5.
|
|
|
||
Item 6.
|
|
|
||
|
|
|
|
September 30,
2017 |
|
December 31,
2016 |
||||
ASSETS
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
9,411
|
|
|
$
|
14,456
|
|
Restricted cash
|
779
|
|
|
779
|
|
||
Trade accounts receivable, net of allowance of $154 and $118
|
4,077
|
|
|
4,733
|
|
||
Inventories, net
|
7,335
|
|
|
6,158
|
|
||
Prepaid expenses and other current assets
|
634
|
|
|
413
|
|
||
Total current assets
|
22,236
|
|
|
26,539
|
|
||
Property and equipment, net
|
6,376
|
|
|
6,449
|
|
||
Brand name and trademark
|
1,510
|
|
|
1,510
|
|
||
Purchased technology and license rights, net
|
189
|
|
|
215
|
|
||
Goodwill
|
185
|
|
|
185
|
|
||
Deposits
|
84
|
|
|
109
|
|
||
Other assets
|
119
|
|
|
103
|
|
||
Total assets
|
$
|
30,699
|
|
|
$
|
35,110
|
|
|
|
|
|
||||
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
||||
Current liabilities:
|
|
|
|
||||
Accounts payable
|
$
|
1,387
|
|
|
$
|
1,606
|
|
Accrued payroll
|
193
|
|
|
419
|
|
||
Accrued vacation
|
330
|
|
|
404
|
|
||
Current portion of mortgage note payable
|
239
|
|
|
239
|
|
||
Accrued and other liabilities
|
2,657
|
|
|
2,604
|
|
||
Total current liabilities
|
4,806
|
|
|
5,272
|
|
||
Mortgage note payable, net of current portion
|
2,515
|
|
|
2,694
|
|
||
Note payable
|
140
|
|
|
140
|
|
||
Deferred rents
|
11
|
|
|
14
|
|
||
Deferred tax liability
|
564
|
|
|
564
|
|
||
Derivative liabilities
|
146
|
|
|
203
|
|
||
Total liabilities
|
8,182
|
|
|
8,887
|
|
||
STOCKHOLDERS' EQUITY
|
|
|
|
||||
Series B convertible preferred stock, $0.001 par value; 3,588,139 authorized and zero issued and outstanding as of September 30, 2017 and 3,588,139 authorized and 975,639 issued and outstanding as of December 31, 2016, respectively
|
—
|
|
|
1
|
|
||
Common stock, $0.001 par value; 75,000,000 shares authorized; 32,975,174 issued and 32,832,095 outstanding as of September 30, 2017 and 40,000,000 shares authorized; 31,002,832 issued and 30,859,753 outstanding as of December 31, 2016, respectively
|
33
|
|
|
31
|
|
||
Additional paid-in capital
|
50,156
|
|
|
49,625
|
|
||
Accumulated deficit
|
(27,672
|
)
|
|
(23,434
|
)
|
||
Total stockholders' equity
|
22,517
|
|
|
26,223
|
|
||
Total liabilities and stockholders' equity
|
$
|
30,699
|
|
|
$
|
35,110
|
|
|
Three Months Ended
September 30, |
|
Nine Months Ended
September 30, |
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Sales
|
$
|
9,347
|
|
|
$
|
10,063
|
|
|
$
|
27,535
|
|
|
$
|
27,133
|
|
Cost of sales
|
4,753
|
|
|
5,002
|
|
|
13,673
|
|
|
14,049
|
|
||||
Gross profit
|
4,594
|
|
|
5,061
|
|
|
13,862
|
|
|
13,084
|
|
||||
Other costs and expenses:
|
|
|
|
|
|
|
|
||||||||
Research and development
|
610
|
|
|
681
|
|
|
2,015
|
|
|
1,941
|
|
||||
Professional services
|
421
|
|
|
292
|
|
|
1,291
|
|
|
1,045
|
|
||||
Salaries and related costs
|
2,080
|
|
|
2,192
|
|
|
6,783
|
|
|
6,492
|
|
||||
Selling, general and administrative
|
2,617
|
|
|
2,141
|
|
|
7,950
|
|
|
6,354
|
|
||||
Total other costs and expenses
|
5,728
|
|
|
5,306
|
|
|
18,039
|
|
|
15,832
|
|
||||
Loss from operations
|
(1,134
|
)
|
|
(245
|
)
|
|
(4,177
|
)
|
|
(2,748
|
)
|
||||
Interest expense, net
|
(36
|
)
|
|
(37
|
)
|
|
(103
|
)
|
|
(125
|
)
|
||||
Change in fair value of derivative liabilities
|
(69
|
)
|
|
(683
|
)
|
|
57
|
|
|
(555
|
)
|
||||
Total other loss, net
|
(105
|
)
|
|
(720
|
)
|
|
(46
|
)
|
|
(680
|
)
|
||||
Loss before income taxes
|
(1,239
|
)
|
|
(965
|
)
|
|
(4,223
|
)
|
|
(3,428
|
)
|
||||
Income tax expense
|
6
|
|
|
—
|
|
|
15
|
|
|
—
|
|
||||
Net loss
|
$
|
(1,245
|
)
|
|
$
|
(965
|
)
|
|
$
|
(4,238
|
)
|
|
$
|
(3,428
|
)
|
|
|
|
|
|
|
|
|
||||||||
Loss per share
|
|
|
|
|
|
|
|
||||||||
Basic
|
$
|
(0.04
|
)
|
|
$
|
(0.04
|
)
|
|
$
|
(0.14
|
)
|
|
$
|
(0.13
|
)
|
Diluted
|
$
|
(0.04
|
)
|
|
$
|
(0.04
|
)
|
|
$
|
(0.14
|
)
|
|
$
|
(0.13
|
)
|
|
|
|
|
|
|
|
|
||||||||
Weighted average number of shares outstanding - basic
|
31,078
|
|
|
27,075
|
|
|
30,932
|
|
|
27,059
|
|
||||
Weighted average number of shares outstanding - dilutive
|
31,078
|
|
|
27,075
|
|
|
30,932
|
|
|
27,059
|
|
|
Preferred Stock
|
|
Common Stock
|
|
|
|
|
|
|
||||||||||||||||
|
Shares
|
|
Par Value
|
|
Shares
|
|
Par Value
|
|
Additional Paid-In Capital
|
|
Accumulated Deficit
|
|
Total
|
||||||||||||
Balance
December 31, 2015 |
1,976
|
|
|
$
|
2
|
|
|
27,051
|
|
|
$
|
27
|
|
|
$
|
42,859
|
|
|
$
|
(19,484
|
)
|
|
$
|
23,404
|
|
Options exercised
|
—
|
|
|
—
|
|
|
31
|
|
|
—
|
|
|
119
|
|
|
—
|
|
|
119
|
|
|||||
Warrants exercised
|
—
|
|
|
—
|
|
|
133
|
|
|
—
|
|
|
316
|
|
|
—
|
|
|
316
|
|
|||||
Stock based compensation
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
533
|
|
|
—
|
|
|
533
|
|
|||||
Stock swap to acquire options and warrants
|
—
|
|
|
—
|
|
|
(73
|
)
|
|
—
|
|
|
(315
|
)
|
|
—
|
|
|
(315
|
)
|
|||||
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(3,428
|
)
|
|
(3,428
|
)
|
|||||
Balance
September 30, 2016 |
1,976
|
|
|
$
|
2
|
|
|
27,142
|
|
|
$
|
27
|
|
|
$
|
43,512
|
|
|
$
|
(22,912
|
)
|
|
$
|
20,629
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Balance
December 31, 2016 |
976
|
|
|
$
|
1
|
|
|
30,860
|
|
|
$
|
31
|
|
|
$
|
49,625
|
|
|
$
|
(23,434
|
)
|
|
$
|
26,223
|
|
Options exercised
|
—
|
|
|
—
|
|
|
21
|
|
|
—
|
|
|
275
|
|
|
—
|
|
|
275
|
|
|||||
Conversion of Series B convertible preferred to common stock
|
(976
|
)
|
|
(1
|
)
|
|
1,951
|
|
|
2
|
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
|||||
Stock based compensation
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
532
|
|
|
—
|
|
|
532
|
|
|||||
Stock swap to acquire options and warrants
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(275
|
)
|
|
—
|
|
|
(275
|
)
|
|||||
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(4,238
|
)
|
|
(4,238
|
)
|
|||||
Balance
September 30, 2017 |
—
|
|
|
$
|
—
|
|
|
32,832
|
|
|
$
|
33
|
|
|
$
|
50,156
|
|
|
$
|
(27,672
|
)
|
|
$
|
22,517
|
|
|
Nine Months Ended September 30,
|
||||||
|
2017
|
|
2016
|
||||
Cash flows from operating activities
|
|
|
|
||||
Net loss
|
$
|
(4,238
|
)
|
|
$
|
(3,428
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
||||
Depreciation and amortization
|
527
|
|
|
556
|
|
||
Provision for inventory obsolescence
|
203
|
|
|
365
|
|
||
Gain on disposal of property and equipment, net
|
3
|
|
|
19
|
|
||
Stock based compensation
|
532
|
|
|
533
|
|
||
Change in fair value of derivative liabilities
|
(57
|
)
|
|
555
|
|
||
Provision for allowance for doubtful accounts
|
128
|
|
|
126
|
|
||
Provision for deferred taxes
|
—
|
|
|
25
|
|
||
Changes in current assets and liabilities:
|
|
|
|
||||
Trade receivables
|
528
|
|
|
(1,070
|
)
|
||
Prepaid expenses
|
(221
|
)
|
|
(48
|
)
|
||
Inventories
|
(1,380
|
)
|
|
(337
|
)
|
||
Deposits and other assets
|
9
|
|
|
312
|
|
||
Accounts payable
|
(219
|
)
|
|
436
|
|
||
Accrued and other liabilities
|
(250
|
)
|
|
(337
|
)
|
||
Net cash used in operating activities
|
(4,435
|
)
|
|
(2,293
|
)
|
||
Cash flows from investing activities
|
|
|
|
||||
Purchases of technology, property and equipment
|
(431
|
)
|
|
(182
|
)
|
||
Net cash used in investing activities
|
(431
|
)
|
|
(182
|
)
|
||
Cash flows from financing activities
|
|
|
|
||||
Proceeds from stock options/warrants exercised
|
—
|
|
|
119
|
|
||
Change in restricted cash
|
—
|
|
|
60
|
|
||
Repayment of mortgage note payable
|
(179
|
)
|
|
(180
|
)
|
||
Net cash used in financing activities
|
(179
|
)
|
|
(1
|
)
|
||
Net change in cash and cash equivalents
|
(5,045
|
)
|
|
(2,476
|
)
|
||
Cash and cash equivalents, beginning of period
|
14,456
|
|
|
11,805
|
|
||
Cash and cash equivalents, end of period
|
$
|
9,411
|
|
|
$
|
9,329
|
|
|
|
|
|
||||
Cash paid for:
|
|
|
|
||||
Interest paid
|
$
|
103
|
|
|
$
|
125
|
|
(In thousands)
|
September 30,
2017 |
|
December 31,
2016 |
||||
Raw materials
|
$
|
5,145
|
|
|
$
|
4,521
|
|
Finished goods
|
3,804
|
|
|
3,048
|
|
||
Gross inventories
|
8,949
|
|
|
7,569
|
|
||
Less: reserve for obsolescence
|
(1,614
|
)
|
|
(1,411
|
)
|
||
Net inventories
|
$
|
7,335
|
|
|
$
|
6,158
|
|
(In thousands)
|
September 30,
2017 |
|
December 31,
2016 |
||||
Brand name and trademark (life indefinite)
|
$
|
1,510
|
|
|
$
|
1,510
|
|
|
|
|
|
||||
Purchased technology (5-17 year lives)
|
$
|
1,496
|
|
|
$
|
1,441
|
|
Less: accumulated amortization
|
(1,307
|
)
|
|
(1,226
|
)
|
||
Purchased technology, net
|
$
|
189
|
|
|
$
|
215
|
|
|
|
|
|
||||
Goodwill
|
$
|
185
|
|
|
$
|
185
|
|
(in thousands)
|
2013
Placement Agent Warrants
|
||
Balance, December 31, 2016
|
$
|
203
|
|
Change in fair value
|
(57
|
)
|
|
Balance, September 30, 2017
(1)
|
$
|
146
|
|
(1)
|
The warrants are valued using a trinomial lattice valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments. Significant assumptions used in the model at
September 30, 2017
included the market price of our common stock, an expected dividend yield of
zero
, the remaining period to the expiration date of the warrants, expected volatility of our common stock over the remaining life of the warrants of
2.0 years
, estimated based on a review of our historical volatility of
60.290%
and risk-free rates of return of
1.380%
for the 2013 warrants based on constant maturity rates published by the U.S. Federal Reserve, applicable to the remaining life of the warrants. We also take into consideration a probability assumption for anti-dilution.
|
|
Three Months Ended
September 30, |
|
Nine Months Ended
September 30, |
||||||||||||
(in thousands, except per share data)
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Numerator:
|
|
|
|
|
|
|
|
||||||||
Net loss available to common shareholders
|
$
|
(1,245
|
)
|
|
$
|
(965
|
)
|
|
$
|
(4,238
|
)
|
|
$
|
(3,428
|
)
|
Effect of dilutive securities:
|
|
|
|
|
|
|
|
||||||||
Derivative liability - warrants
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Numerator for dilutive loss per common share
|
$
|
(1,245
|
)
|
|
$
|
(965
|
)
|
|
$
|
(4,238
|
)
|
|
$
|
(3,428
|
)
|
|
|
|
|
|
|
|
|
||||||||
Denominator:
|
|
|
|
|
|
|
|
||||||||
Weighted average shares used to compute basic loss per common share
|
31,078
|
|
|
27,075
|
|
|
30,932
|
|
|
27,059
|
|
||||
Effect of dilutive securities:
|
|
|
|
|
|
|
|
||||||||
Derivative liability - warrants
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Denominator for dilutive loss per common share
|
31,078
|
|
|
27,075
|
|
|
30,932
|
|
|
27,059
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Basic loss per common share
|
$
|
(0.04
|
)
|
|
$
|
(0.04
|
)
|
|
$
|
(0.14
|
)
|
|
$
|
(0.13
|
)
|
Diluted loss per common share
|
$
|
(0.04
|
)
|
|
$
|
(0.04
|
)
|
|
$
|
(0.14
|
)
|
|
$
|
(0.13
|
)
|
|
Number of options
|
|
Weighted average exercise price
|
|||
Outstanding at December 31, 2016
|
3,752,209
|
|
|
$
|
3.04
|
|
Granted
|
628,000
|
|
|
3.26
|
|
|
Exercised
|
(104,500
|
)
|
|
2.64
|
|
|
Canceled and forfeited
|
(196,803
|
)
|
|
4.99
|
|
|
Outstanding at September 30, 2017
|
4,078,906
|
|
|
$
|
2.99
|
|
|
2017 Grants
|
||||||
Option value
|
$
|
1.73
|
|
-
|
$
|
2.34
|
|
Risk-free rate
|
1.5%
|
||||||
Expected dividend yield
|
—%
|
||||||
Expected volatility
|
68.0%
|
||||||
Expected term (in years)
|
6
|
(In thousands)
|
Long-term debt
|
||
2017
(remaining three months)
|
$
|
60
|
|
2018
|
239
|
|
|
2019
|
2,455
|
|
|
Total
|
$
|
2,754
|
|
|
Three Months Ended September 30, 2017
|
||||||||||||||||||
(In thousands)
|
Core
|
|
OEM
|
|
Advanced Energy
|
|
Corporate (Other)
|
|
Total
|
||||||||||
Sales
|
$
|
6,696
|
|
|
$
|
525
|
|
|
$
|
2,126
|
|
|
$
|
—
|
|
|
$
|
9,347
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Income (loss) from operations
(1)
|
1,699
|
|
|
323
|
|
|
(718
|
)
|
|
(2,438
|
)
|
|
(1,134
|
)
|
|||||
|
|
|
|
|
|
|
|
|
|
||||||||||
Interest expense, net
|
—
|
|
|
—
|
|
|
—
|
|
|
(36
|
)
|
|
(36
|
)
|
|||||
Change in fair value of derivative liabilities
|
—
|
|
|
—
|
|
|
—
|
|
|
(69
|
)
|
|
(69
|
)
|
|||||
Income tax expense
|
—
|
|
|
—
|
|
|
—
|
|
|
6
|
|
|
6
|
|
|||||
Depreciation and amortization
|
—
|
|
|
—
|
|
|
—
|
|
|
171
|
|
|
171
|
|
|
Three Months Ended September 30, 2016
|
||||||||||||||||||
(In thousands)
|
Core
|
|
OEM
|
|
Advanced Energy
|
|
Corporate (Other)
|
|
Total
|
||||||||||
Sales
|
$
|
6,902
|
|
|
$
|
1,762
|
|
|
$
|
1,399
|
|
|
$
|
—
|
|
|
$
|
10,063
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Income (loss) from operations
|
2,089
|
|
|
690
|
|
|
(707
|
)
|
|
(2,317
|
)
|
|
(245
|
)
|
|||||
|
|
|
|
|
|
|
|
|
|
||||||||||
Interest expense, net
|
—
|
|
|
—
|
|
|
—
|
|
|
(37
|
)
|
|
(37
|
)
|
|||||
Change in fair value of derivative liabilities
|
—
|
|
|
—
|
|
|
—
|
|
|
(683
|
)
|
|
(683
|
)
|
|||||
Income tax expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Depreciation and amortization
|
—
|
|
|
—
|
|
|
—
|
|
|
201
|
|
|
201
|
|
|
Nine Months Ended September 30, 2017
|
||||||||||||||||||
(In thousands)
|
Core
|
|
OEM
|
|
Advanced Energy
|
|
Corporate (Other)
|
|
Total
|
||||||||||
Sales
|
$
|
20,959
|
|
|
$
|
2,030
|
|
|
$
|
4,546
|
|
|
$
|
—
|
|
|
$
|
27,535
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Income (loss) from operations
(1)
|
6,471
|
|
|
1,031
|
|
|
(3,821
|
)
|
|
(7,858
|
)
|
|
(4,177
|
)
|
|||||
|
|
|
|
|
|
|
|
|
|
||||||||||
Interest expense, net
|
—
|
|
|
—
|
|
|
—
|
|
|
(103
|
)
|
|
(103
|
)
|
|||||
Change in fair value of derivative liabilities
|
—
|
|
|
—
|
|
|
—
|
|
|
57
|
|
|
57
|
|
|||||
Income tax expense
|
—
|
|
|
—
|
|
|
—
|
|
|
15
|
|
|
15
|
|
|||||
Depreciation and amortization
|
—
|
|
|
—
|
|
|
—
|
|
|
527
|
|
|
527
|
|
|
Nine Months Ended September 30, 2016
|
||||||||||||||||||
(In thousands)
|
Core
|
|
OEM
|
|
Advanced Energy
|
|
Corporate (Other)
|
|
Total
|
||||||||||
Sales
|
$
|
20,261
|
|
|
$
|
4,351
|
|
|
$
|
2,521
|
|
|
$
|
—
|
|
|
$
|
27,133
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Income (loss) from operations
|
5,047
|
|
|
2,498
|
|
|
(3,331
|
)
|
|
(6,962
|
)
|
|
(2,748
|
)
|
|||||
|
|
|
|
|
|
|
|
|
|
||||||||||
Interest expense, net
|
—
|
|
|
—
|
|
|
—
|
|
|
(125
|
)
|
|
(125
|
)
|
|||||
Change in fair value of derivative liabilities
|
—
|
|
|
—
|
|
|
—
|
|
|
(555
|
)
|
|
(555
|
)
|
|||||
Income tax expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Depreciation and amortization
|
—
|
|
|
—
|
|
|
—
|
|
|
355
|
|
|
556
|
|
(1)
|
During the first and second quarter of 2017, marketing expenses were considered as attributable only to the Corporate (Other) segment in the line Income (loss) from operations. Beginning with the third quarter of 2017, it was determined that certain marketing expenses are attributable to specific segments. The disclosure of Income (loss) from operations was updated for the third quarter of 2017 to reflect marketing expense by segment.
|
|
Three Months Ended
September 30, |
|
Nine Months Ended
September 30, |
||||||||||||
(In thousands)
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Sales by Product Line
|
|
|
|
|
|
|
|
||||||||
Electrosurgical
|
$
|
6,205
|
|
|
$
|
5,690
|
|
|
$
|
17,741
|
|
|
$
|
15,020
|
|
Cauteries
|
1,696
|
|
|
1,863
|
|
|
5,224
|
|
|
5,417
|
|
||||
Lighting
|
573
|
|
|
740
|
|
|
1,966
|
|
|
2,046
|
|
||||
Other
|
873
|
|
|
1,770
|
|
|
2,604
|
|
|
4,650
|
|
||||
Total
|
$
|
9,347
|
|
|
$
|
10,063
|
|
|
$
|
27,535
|
|
|
$
|
27,133
|
|
|
Three Months Ended
September 30, |
|
Nine Months Ended
September 30, |
||||||||||||
(In thousands)
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Sales by Domestic and International
|
|
|
|
|
|
|
|
||||||||
Domestic
|
$
|
7,978
|
|
|
$
|
8,730
|
|
|
$
|
23,678
|
|
|
$
|
23,102
|
|
International
|
1,369
|
|
|
1,333
|
|
|
3,857
|
|
|
4,031
|
|
||||
Total
|
$
|
9,347
|
|
|
$
|
10,063
|
|
|
$
|
27,535
|
|
|
$
|
27,133
|
|
|
Three Months Ended
September 30, |
|
|
|
Nine Months Ended
September 30, |
|
|
||||||||||||||
(In thousands)
|
2017
|
|
2016
|
|
Change
|
|
2017
|
|
2016
|
|
Change
|
||||||||||
Sales by Reportable Segment
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Core
|
$
|
6,696
|
|
|
$
|
6,902
|
|
|
(3.0
|
)%
|
|
$
|
20,959
|
|
|
$
|
20,261
|
|
|
3.4
|
%
|
OEM
|
525
|
|
|
1,762
|
|
|
(70.2
|
)%
|
|
2,030
|
|
|
4,351
|
|
|
(53.3
|
)%
|
||||
Advanced Energy
|
2,126
|
|
|
1,399
|
|
|
52.0
|
%
|
|
4,546
|
|
|
2,521
|
|
|
80.3
|
%
|
||||
Total
|
$
|
9,347
|
|
|
$
|
10,063
|
|
|
(7.1
|
)%
|
|
$
|
27,535
|
|
|
$
|
27,133
|
|
|
1.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Sales by Product Line
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Electrosurgical
|
$
|
6,205
|
|
|
$
|
5,690
|
|
|
9.1
|
%
|
|
$
|
17,741
|
|
|
$
|
15,020
|
|
|
18.1
|
%
|
Cauteries
|
1,696
|
|
|
1,863
|
|
|
(9.0
|
)%
|
|
5,224
|
|
|
5,417
|
|
|
(3.6
|
)%
|
||||
Lighting
|
573
|
|
|
740
|
|
|
(22.6
|
)%
|
|
1,966
|
|
|
2,046
|
|
|
(3.9
|
)%
|
||||
Other
|
873
|
|
|
1,770
|
|
|
(50.7
|
)%
|
|
2,604
|
|
|
4,650
|
|
|
(44.0
|
)%
|
||||
Total
|
$
|
9,347
|
|
|
$
|
10,063
|
|
|
(7.1
|
)%
|
|
$
|
27,535
|
|
|
$
|
27,133
|
|
|
1.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Sales by Domestic and International
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Domestic
|
$
|
7,978
|
|
|
$
|
8,730
|
|
|
(8.6
|
)%
|
|
$
|
23,678
|
|
|
$
|
23,102
|
|
|
2.5
|
%
|
International
|
1,369
|
|
|
1,333
|
|
|
2.7
|
%
|
|
3,857
|
|
|
4,031
|
|
|
(4.3
|
)%
|
||||
Total
|
$
|
9,347
|
|
|
$
|
10,063
|
|
|
(7.1
|
)%
|
|
$
|
27,535
|
|
|
$
|
27,133
|
|
|
1.5
|
%
|
|
Three Months Ended
September 30, |
|
|
|
Nine Months Ended
September 30, |
|
|
||||||||||||||
(In thousands)
|
2017
|
|
2016
|
|
Change
|
|
2017
|
|
2016
|
|
Change
|
||||||||||
Cost of sales
|
$
|
4,753
|
|
|
$
|
5,002
|
|
|
(5.0
|
)%
|
|
$
|
13,673
|
|
|
$
|
14,049
|
|
|
(2.7
|
)%
|
Percentage of revenue
|
50.9
|
%
|
|
49.7
|
%
|
|
|
|
|
49.7
|
%
|
|
51.8
|
%
|
|
|
|
Gross profit
|
$
|
4,594
|
|
|
$
|
5,061
|
|
|
(9.2
|
)%
|
|
$
|
13,862
|
|
|
$
|
13,084
|
|
|
5.9
|
%
|
Percentage of revenue
|
49.1
|
%
|
|
50.3
|
%
|
|
(1.2
|
)%
|
|
50.3
|
%
|
|
48.2
|
%
|
|
2.1
|
%
|
|
Three Months Ended
September 30, |
|
|
|
Nine Months Ended
September 30, |
|
|
||||||||||||||
(In thousands)
|
2017
|
|
2016
|
|
Change
|
|
2017
|
|
2016
|
|
Change
|
||||||||||
Research and Development expense
|
$
|
610
|
|
|
$
|
681
|
|
|
(10.4
|
)%
|
|
$
|
2,015
|
|
|
$
|
1,941
|
|
|
3.8
|
%
|
Percentage of revenue
|
6.5
|
%
|
|
6.8
|
%
|
|
|
|
7.3
|
%
|
|
7.2
|
%
|
|
0.1
|
%
|
|
Three Months Ended
September 30, |
|
|
|
Nine Months Ended
September 30, |
|
|
||||||||||||||
(In thousands)
|
2017
|
|
2016
|
|
Change
|
|
2017
|
|
2016
|
|
Change
|
||||||||||
Professional services expense
|
$
|
421
|
|
|
$
|
292
|
|
|
44.2
|
%
|
|
$
|
1,291
|
|
|
$
|
1,045
|
|
|
23.4
|
%
|
Percentage of revenue
|
4.5
|
%
|
|
2.9
|
%
|
|
1.6
|
%
|
|
4.7
|
%
|
|
3.9
|
%
|
|
0.8
|
%
|
|
Three Months Ended
September 30, |
|
|
|
Nine Months Ended
September 30, |
|
|
||||||||||||||
(In thousands)
|
2017
|
|
2016
|
|
Change
|
|
2017
|
|
2016
|
|
Change
|
||||||||||
Salaries and related expenses
|
$
|
2,080
|
|
|
$
|
2,192
|
|
|
(5.1
|
)%
|
|
$
|
6,783
|
|
|
$
|
6,492
|
|
|
4.5
|
%
|
Percentage of revenue
|
22.3
|
%
|
|
21.8
|
%
|
|
|
|
24.6
|
%
|
|
23.9
|
%
|
|
|
|
Three Months Ended
September 30, |
|
|
|
Nine Months Ended
September 30, |
|
|
||||||||||||||
(In thousands)
|
2017
|
|
2016
|
|
Change
|
|
2017
|
|
2016
|
|
Change
|
||||||||||
SG&A Expense
|
$
|
2,617
|
|
|
$
|
2,141
|
|
|
22.2
|
%
|
|
$
|
7,950
|
|
|
$
|
6,354
|
|
|
25.1
|
%
|
Percentage of revenue
|
28.0
|
%
|
|
21.3
|
%
|
|
|
|
28.9
|
%
|
|
23.4
|
%
|
|
|
|
Three Months Ended
September 30, |
|
|
|
Nine Months Ended
September 30, |
|
|
||||||||||||||
(In thousands)
|
2017
|
|
2016
|
|
Change
|
|
2017
|
|
2016
|
|
Change
|
||||||||||
Interest expense, net
|
$
|
(36
|
)
|
|
$
|
(37
|
)
|
|
(2.7
|
)%
|
|
$
|
(103
|
)
|
|
$
|
(125
|
)
|
|
(17.6
|
)%
|
Percentage of revenue
|
(0.4
|
)%
|
|
(0.4
|
)%
|
|
|
|
(0.4
|
)%
|
|
(0.5
|
)%
|
|
|
||||||
Change in fair value of derivative liabilities
|
$
|
(69
|
)
|
|
$
|
(683
|
)
|
|
(89.9
|
)%
|
|
$
|
57
|
|
|
$
|
(555
|
)
|
|
(110.3
|
)%
|
Percentage of revenue
|
(0.7
|
)%
|
|
(6.8
|
)%
|
|
|
|
0.2
|
%
|
|
(2.0
|
)%
|
|
|
3.1
|
|
|
3.2
|
|
|
3.3
|
|
|
3.4
|
|
|
3.5*
|
|
|
31.1*
|
|
|
31.2*
|
|
|
32.1*
|
|
|
32.2*
|
|
|
101.INS**
|
|
XBRL Instance Document
|
101.SCH**
|
|
XBRL Taxonomy Extension Schema Document
|
101.CAL**
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
101.DEF**
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
101.LAB**
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
101.PRE**
|
|
XBRL Taxonomy Extension Label Presentation Document
|
|
Bovie Medical Corporation
|
|
|
|
|
|
|
Date: November 3, 2017
|
By:
|
/s/ Robert L. Gershon
|
|
|
|
Robert L. Gershon
|
|
|
|
Chief Executive Officer and Director
|
|
|
|
(Principal Executive Officer)
|
|
|
|
|
|
Date: November 3, 2017
|
By:
|
/s/ Jay D. Ewers
|
|
|
|
Jay D. Ewers
|
|
|
|
Chief Financial Officer,
|
|
|
|
Treasurer and Secretary
|
|
|
|
(Principal Financial Officer)
|
|
1 Year Bovie Chart |
1 Month Bovie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions